MedTrace Logo

Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer

NCT06292286 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-06-11

No results posted yet for this study

Summary

About 80% of advanced ovarian cancer patients recurred in 2-3 years. Secondary cytoreduction benefits selected patients who have high chance of complete resection. Whether secondary interval surgery can be used at recurrence is not known.

Conditions

  • Recurrent Ovarian Carcinoma

Interventions

PROCEDURE

Carboplatin or cisplatin

Carboplatin of cisplatin for 3-6 cycles

DRUG

Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar

Paclitaxel, gemcitabine or liposomal doxorubicin, for 3-6 cycles

DRUG

Bevacizumab or biosimilar

Optional

PROCEDURE

Cytoreductive surgery

Cytoreductive surgery after chemotherapy

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Ka Yu Tse · The University of Hong Kong

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06292286 on ClinicalTrials.gov